The Protein Interactions Expert


Meet us at Writing and Editing the Ubiquitine Code

Bilbao, Spain - 26-27 February

Meet us at the Writing and Editing the Ubiquitine Code conference in Bilbao, Spain from February 26th to 27th, 2019.

This international meeting will gather experts and scientists from all over the world to discuss the latest advances regarding Post-translational modifications (PTM) by members of the ubiquitin family.

Dr. Jean-Christophe Rain, CSO, will attend this event. He will be happy to meet you and present our antibodies tools to study the ubiquitin modifications.

Feel free to Contact us to arrange a meeting with him to discuss your project.

Meet us at LS2 meeting – Cells, Molecules and Organisms

Zurich, Switzerland - 13-14 Feb

Meet us at the LS2 meeting – Cells, Molecules and Organismsin Zurich, Switzerland from February 13th to 14th , 2020.

This conference will bring together scientists from all nations and backgrounds to explore the large spectrum united under the umbrella of Life Sciences

Söhnke Kühnhold Business Development Manager will attend this event. He will be happy to meet you and present our services, ULTImate Y2H, ULTImate YChemH, Hybribody.

Feel free to contact us to arrange a meeting with our team!


A new incredible interaction map of chromosome 21 proteins :

Evry, France - January 22

“Chr21 protein-protein interactions: enrichment in products involved in intellectual disabilities, autism and Late Onset Alzheimer Disease” on BioRxiv.

More than 1500 interactionswere identified by Yeast two-hybrid with their interacting domains. All the data will be published on intact as well.

This article brings new knowledge on trisomie21 and brain functions.

This Massive Scientific Program was financed by Jerome Lejeune Foundation


Hybrigenics Services is fully independent from Hybrigenics Pharma

Evry, France - October 16, 2019

Please note that Hybrigenics Services ( and Hybrigenics Pharma ( have been two financially independent companies since January 2017 despite keeping similar names. Our activities are completely distinct and our operations entirely separate.

Hybrigenics Pharma announced on October 23, 2018 that the clinical development of its only drug candidate was discontinued for lack of efficacy. The winding-up of the company was suspended in January, 2019 when Hybrigenics Pharma received a takeover offer. On October 15, 2019 Hybrigenics Pharma announced its takeover by DMS Group with immediate effect.

None of this affects Hybrigenics Services in any way, nor the research we conduct for our clients and partners. We regret the confusion this might cause.

We thank investigators and companies across the world for their trust and continued interest in our services.

Old news

Back to Top